Go to content Go to menu Go to search

Vivalis: opening of a new laboratory in the Lyon Gerland biotechnology district

10 February 2012

  • version française

Vivalis announced, on 23th January 2012, the opening of a new facility for partnered VIVA|ScreenTM antibody discovery programs in the Lyon Gerland biotechnology district.

The Lyon Gerland biotechnology district offers the advantages of a centralized, world-class research and production environment in human and animal health. Resident companies include the likes of Sanofi Pasteur, Merial, and Genzyme along with research institutions such as the French Institute for Protein Biology and Chesmistry.

With this new state-of-the-art laboratory, Vivalis will be able to expand its research and development capacity and strengthen the VIVA|ScreenTM platform in current and future industrial collaborations.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of Vivalis jointly stated, "Since implementing the microarray technology into our antibody discovery plateform, the demand for partnered activities and research into continually improving the technology has been at the forefront of our discovery efforts. Our capacity to engage in new clients programs and advance the platform becomes central to the success of Vivalis as a whole and this new facility gives us the resources and power to do so."

Find out more

Vivalis is a biopharmaceutical company that provides innovative cell solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. Vivalis' expertise and intellectual property are leveraged in three main areas:

  • EB66® cell line;
  • VIVA|ScreenTM human antibody discovery platform; 
  • 3D-ScreenTM drug discovery platform.

Based in Nantes & Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Grimaud Group, worldwide leader in animal genetic selection.

Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health, and SAFC Biosciences.

Vivalis is a member of: 

  • the French Atlantic Biotherapies and Lyonbiopôle bioclusters; 
  • the Japanese Okuriku innovation cluster for health science in Toyama.